Menu Search
Equities

CytomX Therapeutics Inc

6C1:FRA

CytomX Therapeutics Inc

Actions
  • Price (EUR)0.8655
  • Today's Change-0.052 / -5.62%
  • Shares traded1.05k
  • 1 Year change-21.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 10:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CytomX Therapeutics Inc grew revenues 90.38% from 53.16m to 101.21m while net income improved from a loss of 99.32m to a smaller loss of 569.00k.
Gross margin--
Net profit margin10.92%
Operating margin5.30%
Return on assets7.68%
Return on equity--
Return on investment29.38%
More ▼

Cash flow in USDView more

In 2023, cash reserves at CytomX Therapeutics Inc fell by 176.48m. Cash Flow from Financing totalled 30.23m or 29.87% of revenues. In addition the company used 56.04m for operations while cash used for investing totalled 150.67m.
Cash flow per share0.1875
Price/Cash flow per share5.19
Book value per share-0.2998
Tangible book value per share-0.3198
More ▼

Balance sheet in USDView more

CytomX Therapeutics Inc uses little or no debt in its capital structure.
Current ratio1.04
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.